Publication | Closed Access

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

Hematological MalignancyOncologyHematologyMyeloid NeoplasiaOral DexamethasonePharmacotherapyPanorama 3MedicineRadiation OncologyRefractory Multiple MyelomaHealth Sciences